shcri.com - Digital breast tomosynthesis (DBT) is due to revive the breast cancer imaging market in the developed world, installations expected to increase four fold in the US by 2016, and double in the EU, according to Breast Cancer Imaging - Global Analysis and Market Forecasts.
Breast Cancer Imaging - Global Analysis and Market Forecasts states that the US is the biggest contributor in the global breast cancer imaging market, and US revenues dipped for new installations of full-field digital mammography equipment after 2009, when the US market began to show signs of saturation. However, the positive reception of DBT by the radiology community may help the market out of this slump. GlobalData predicts that DBT's share in new breast imaging system installations in the US alone will grow from 10% in 2011 to a 75% share in 2018, leading the global breast cancer imaging market to grow from a value of $972m in 2011 to $1.7 billion by 2018.
DBT is a 3D imaging technique which uses a moving X-ray tube to capture various images to be reconstructed into a 3D structure of the breast. DBT is predicted to be the future gold standard technology in the breast cancer screening industry, due to its promising increase in cancer detection and reduction of false-positives, which represent key concerns with mammography.
Hologic was the first company to bring DBT to the US market, and is currently the only player with an FDA-approved DBT system. Competitors such as GE Healthcare and Siemens introduced DBT into non-US markets around 2008, but have not yet received FDA approval for their products, providing Hologic the opportunity to establish itself as the US market leader.
Trials will play a significant role in the fate of the DBT market. The ongoing Oslo Breast Cancer Screening Trial is estimated to enroll 25,000 women to evaluate the effectiveness of DBT. Interim results released earlier this year were promising, showing that using DBT in combination with conventional 2D mammography improved the detection rate of all cancers by 27%, a 40% increase in the detection of invasive cancers, and reduced false-positive rates by 15% when compared to 2D mammography alone. Hologic stated that it observed a significant increase in interest levels for DBT after the release of this initial data, and full trial results in 2015 are expected to further validate the push towards DBT as the paradigm in breast cancer detection in the future, quantifying the benefits offered over current screening methods.
The UK's National Institute for Health Research (NIHR) is also currently conducting a DBT trial, TOMMY, due to be completed in 2015 and is expected to set the benchmark for the future national uptake of DBT. GlobalData predicts that new installations for DBT are likely to double in the UK by 2016, and the conclusions of TOMMY in 2015 will lend credence to this forecast.
Some barriers still remain, however. DBT systems may be ruled out if clinics cannot afford them, and lack of reimbursement is also a challenge. In addition, DBT has a higher radiation dose exposure than mammography, but GlobalData expects that two-dimensional (2D) synthetic mammograms will provide a means of reducing the radiation dose when DBT is employed on its own.
This report provides an analysis of the mammography market (in relation to dedicated breast cancer screening and diagnosis), in the US, the 5EU (France, Germany, Italy, Spain, and UK), Brazil, and the APAC regions, including Japan, China, and India, and identifies the unmet needs in the market. It also discusses physician attitudes towards current breast cancer screening and diagnostic techniques, and the future of breast cancer imaging modalities in the face of rapid technological advancements.